Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF82422 in Multiple System Atrophy
NCT05104476Phase 2Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of amlenetug in multiple system atrophy (MSA), sponsored by Lundbeck. Started Nov 2021; status: active, not recruiting.
02
Drugs
amlenetug
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05104476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104476.